Al-Mterin Mohammad A, Elkord Eyad
Natural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman.
Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, M5 4WT Manchester, UK.
Explor Target Antitumor Ther. 2022;3(4):497-510. doi: 10.37349/etat.2022.00097. Epub 2022 Aug 31.
Myeloid-derived suppressor cells (MDSCs) are a group of immature myeloid cells, which are expanded in most cancer patients. MDSCs suppress host immune responses, leading to cancer growth and progression. Several studies demonstrated that there was a relationship between levels of MDSCs and tumorigenesis in colorectal cancer (CRC) patients. MDSCs are now being investigated for their role as possible therapeutic targets in cancer treatment. This review summarizes available studies that investigated MDSC expansion in CRC patients, as well as their role in CRC tumorigenesis, prognosis, and targeting. Based on the available studies, there is a possible relationship between high levels of MDSCs and CRC progression. Additionally, targeting MDSCs in CRC patients selectively represents a significant challenge for the development of targeted treatments. Targeting of MDSCs could be exploited in different ways including MDSC depletion, inhibition of MDSC function and recruitment, and enhancing MDSC differentiation. Overall, MDSCs could be exploited as prognostic biomarkers and potential therapeutic targets in CRC.
髓系来源的抑制性细胞（MDSCs）是一组未成熟的髓细胞，在大多数癌症患者中数量会增加。MDSCs会抑制宿主免疫反应，导致癌症生长和进展。多项研究表明，MDSCs水平与结直肠癌（CRC）患者的肿瘤发生之间存在关联。目前正在研究MDSCs作为癌症治疗中可能的治疗靶点所起的作用。这篇综述总结了有关CRC患者中MDSC扩增情况的现有研究，以及它们在CRC肿瘤发生、预后和靶向治疗方面的作用。基于现有研究，MDSCs水平升高与CRC进展之间可能存在关联。此外，选择性地靶向CRC患者中的MDSCs对开发靶向治疗构成了重大挑战。可以通过不同方式利用对MDSCs的靶向作用，包括清除MDSCs、抑制MDSC功能和募集，以及促进MDSC分化。总体而言，MDSCs可作为CRC的预后生物标志物和潜在治疗靶点。
